厄洛替尼与吉非替尼治疗非小细胞肺癌的疗效与经济优势对比(1)
【摘要】 目的：研究厄洛替尼與吉非替尼两种靶向药物治疗非小细胞肺癌的效果与经济优势。方法：回顾性分析2015年2月-2017年2月在本院接受靶向药物厄洛替尼治疗的40例非小细胞肺癌患者的临床资料，设为厄洛替尼组。另选取同期在本院接受靶向药物吉非替尼治疗的40例非小细胞肺癌患者的临床资料设为吉非替尼组。比较两组的临床疗效、不良反应发生情况以及无进展生存期情况。并通过疾病控制率予以成本-效果分析，通过质量调整生命年予以成本-效用分析。结果：厄洛替尼组与吉非替尼组的疾病控制率分别为75.00%(30/40)、62.50%(25/40)，两组对比差异无统计学意义(P>0.05)。厄洛替尼组与吉非替尼组的皮疹、肝损伤、腹泻等不良反应发生率比较，差异均无统计学意义(P>0.05)。厄洛替尼组与吉非替尼组无进展生存期分别为(378.4±150.1)、(353.2±143.3)d，两组比较差异无统计学意义(P>0.05)。厄洛替尼与吉非替尼的总成本分别为70 552元、84 975元；厄洛替尼与吉非替尼的成本-效果比分别为941、1 360；厄洛替尼与吉非替尼的成本-效用比分别为65 326、87 874，比较差异均有统计学意义(P<0.05)。结论：厄洛替尼与吉非替尼两种靶向药物治疗非小细胞肺癌的疗效、不良反应发生率及无进展生存期相似，但厄洛替尼方案具有更加显著的经济优势。
, http://www.100md.com
【关键词】 非小细胞肺癌； 厄洛替尼； 吉非替尼； 经济优势
【Abstract】 Objective：To study the effects and economic advantages of two targeted drugs，Erlotinib and Gefitinib，in the treatment of non-small cell lung cancer.Method：The clinical data of 40 patients with non-small cell lung cancer treated with targeted drug Erlotinib in our hospital from February 2015 to February 2017 were retrospectively analyzed，and they were set as Erlotinib group.In addition，40 patients with non-small cell lung cancer who received Gefitinib as a targeted drug in our hospital were selected as Gefitinib group.The clinical efficacy，the occurrence of adverse reactions and the progression-free survival were compared between the two groups.Cost-effect analysis was performed by disease control rate and cost-utility analysis by quality adjusted life years.Result：The disease control rates of Erlotinib group and Gefitinib group were 75.00%(30/40) and 62.50%(25/40)，respectively，there was no significant difference between the two groups(P>0.05).There were no significant differences between Erlotinib group and Gefitinib group in the incidence of skin rash，liver injury and diarrhea(P>0.05).The progression free survival time of Erlotinib group and Gefitinib group were(378.4±150.1)d and (353.2±143.3)d respectively，there was no significant difference between the two groups(P>0.05).The total cost of Erlotinib group and Gefitinib group was 70 552 yuan and 84 975 yuan；the cost-effect ratios of Erlotinib group and Gefitinib group were 941 and 1 360 respectively；the cost to utility ratio of Erlotinib group and Gefitinib group was 65 326 and 87 874 respectively，the differences were statistically significant(P<0.05).
Conclusion：Efficacy of two targeted drugs Erlotinib and Gefitinib in the treatment of non-small cell lung cancer，adverse reactions and progression free survival were similar，but Erlotinib has economic advantages., 百拇医药(武乐 刘震天 叶华姝)
, http://www.100md.com
【关键词】 非小细胞肺癌； 厄洛替尼； 吉非替尼； 经济优势
【Abstract】 Objective：To study the effects and economic advantages of two targeted drugs，Erlotinib and Gefitinib，in the treatment of non-small cell lung cancer.Method：The clinical data of 40 patients with non-small cell lung cancer treated with targeted drug Erlotinib in our hospital from February 2015 to February 2017 were retrospectively analyzed，and they were set as Erlotinib group.In addition，40 patients with non-small cell lung cancer who received Gefitinib as a targeted drug in our hospital were selected as Gefitinib group.The clinical efficacy，the occurrence of adverse reactions and the progression-free survival were compared between the two groups.Cost-effect analysis was performed by disease control rate and cost-utility analysis by quality adjusted life years.Result：The disease control rates of Erlotinib group and Gefitinib group were 75.00%(30/40) and 62.50%(25/40)，respectively，there was no significant difference between the two groups(P>0.05).There were no significant differences between Erlotinib group and Gefitinib group in the incidence of skin rash，liver injury and diarrhea(P>0.05).The progression free survival time of Erlotinib group and Gefitinib group were(378.4±150.1)d and (353.2±143.3)d respectively，there was no significant difference between the two groups(P>0.05).The total cost of Erlotinib group and Gefitinib group was 70 552 yuan and 84 975 yuan；the cost-effect ratios of Erlotinib group and Gefitinib group were 941 and 1 360 respectively；the cost to utility ratio of Erlotinib group and Gefitinib group was 65 326 and 87 874 respectively，the differences were statistically significant(P<0.05).
Conclusion：Efficacy of two targeted drugs Erlotinib and Gefitinib in the treatment of non-small cell lung cancer，adverse reactions and progression free survival were similar，but Erlotinib has economic advantages., 百拇医药(武乐 刘震天 叶华姝)
参见：首页 > 医疗版 > 疾病专题 > 呼吸内科 > 肺肿瘤 > 肺癌